History of PLP development - Part #1
Brief Introduction of P.L.P. (Photo-Laser-Phoresis) therapy, and its application for cancer treatment
1. History of Photodynamic therapy development
Photodynamic therapy is the novel approach to treat varieties of diseases where cancer is the main one.
The history of development goes back to 1904 when O. Raab and H. von Tappeiner reported about "photodynamic phenomena" effect which took place after mixing light sensitive agent (eosin) with bacteria culture, leaving Petri dishes under the light exposure for a few hours. The outcome result was the death of pathological microorganisms.
Such accidental discovery lead afterwards professor Thomas Dougherty of Roswell Park Cancer Institute (Buffalo, USA) to develop PDT (Photodynamic Therapy) which is well recognized presently by scientific, medical world and approved by FDA to treat cancer in many countries such as USA, Canada, Russia, Japan, China, Germany, France, UK, just a few to mention.
The main principals of PDT action are as follow:
The agent (photosensitizer; PS) introduced mostly intravenously in to biological organism and then, after some period of time reaching maximum concentration in malignant tissue, activated by light of certain wavelength in nm. Such process of light activation pushes molecule from ground energy state S0 to triplet one T1 producing ROS (Reactive Oxygen Spices) where singlet oxygen O1 is the main compound yielded by such photo-chemical reaction.
The toxic compound (O1) oxidizes cell structure destroying its organelles, triggering the processes, of necrosis followed by apoptosis, known as a preprogramed cell death cascading effects (perforating cell membrane causing lysis of phospholipids into extracellular space).
Although the therapy is safe and non-invasive by comparison to conventional cancer treatments, existing in cancer "industry" but it has many limitations which narrowed down its applications to superficial type of cancers such as BCC or skin lesions - Actinic Keratosis, Acne, Psoriasis etc.
P.L.P. is the latest (2013) invention by R.S.I. Group with professors and experts around the world.
Instead of using just coherent light of one certain wavelength to activate agent, which traditionally used by PDT there are at least three ones working together in a synergy amplifying treatment's outcome effects.
Administered agent is the new chiral form of enzymatically activated photosensitive compound, which is delivered directly into malignant cell through nano particles acting as a "Trojan horse" upon coherent light activation.
The way of agent administration and its activation are completely different and based on main principals of Photo Phoresis rather than conventional PDT ones.
The new way of understanding abnormal cells development in biological system, and key role of “Vital” energy, obtained throughout recent research by R.S.I. Group lead the team to completely different strategy of cancer therapy opening gateway for the new advanced technologies of cancer therapy.